Cerulean Pharma Shifts its Focus to Women’s Health

Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company that develops nanoparticle-drug conjugates (NDCs), sold off its lead assets and is transitioning its focus from oncology to women’s health. The company announced on February 1, 2017 that it had hired investment bank Aquilo Partners, L.P., as its financial advisor to assist in a comprehensive review of strategic alternatives to maximize stockholder value. Then, on March 20, 2017, it announced that it had entered a stock purchase agreement with privately-held Daré Bioscience, in which Daré will own between 51% and 70% of the combined company. Daré Bioscience is a California-based, clinical-stage pharmaceutical company that develops... Read More »